Mark Yarchoan, Associate Professor at Johns Hopkins Hospital and Co-Founder and CSO at Adventris Pharmaceuticals, shared a post on X:
“The timing could not be worse.
At ASCO 2026, we saw daraxonrasib double survival in PDAC, a reminder that decades of NIH research investment are paying off.
Yet federal research funding is being cut. The biggest victims won’t be scientists. They’ll be future patients.”
Other articles featuring Mark Yarchoan on OncoDaily.